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Abstract
Genome-wide association studies (GWAS) in psychiatry, once they reach sufficient sample size 
and power, have been enormously successful. The Psychiatric Genomics Consortium (PGC) aims 
for mega-analyses with sample sizes that will grow to (cumulatively) >1 million individuals in the 
next 5 years. This should lead to hundreds of new findings for common genetic variants across 
nine psychiatric disorders studied by the PGC. The new targets discovered by GWAS have the 
potential to restart largely stalled psychiatric drug development pipelines, and the translation of 
GWAS findings into the clinic is a key aim of the recently funded phase 3 of the PGC. This is not 
without considerable technical challenges. These approaches complement the other main aim of 
GWAS studies on risk prediction approaches for improving detection, differential diagnosis, and 
clinical trial design. This paper outlines the motivations, technical and analytical issues, and the 
plans for translating PGC3 findings into new therapeutics.
The state of drug discovery in psychiatry
In psychiatry, conventional drug discovery is at an impasse1. In 2015, three (cariprazine, 
aripiprazole lauroxil, and brexpiprazole) out of 45 new drugs approved by FDA were related 
to psychiatry. The mechanisms of action of these drugs are not novel as their pharmacology 
primarily targets dopamine and serotonin receptors. There still remain significant unmet 
medical needs and societal costs for psychiatric disorders that necessitate novel 
therapeutics.2 In disorders where partially effective treatments already exist, drug 
development has a higher investment risk, because any new drug has to exceed the clinical 
efficacy of existing treatments, or show equivalent efficacy together with significant 
improvements in safety and tolerability, as well as competing for market share with 
established standards of care. This is particularly difficult where there is a lack of novel 
targets with adequate validation. This has resulted in relatively higher drug discovery and 
development costs and longer than average cycle time in both clinical trial execution and 
regulatory agency review. Some companies have paused or de-prioritised their drug 
discovery and clinical trial efforts in psychiatry3. However, there are many (183) clinical 
trials underway or registered, showing there is still considerable investment in the field. 
(Supp Table 1 provides details of current and recent trials in psychiatry, including the nine 
PGC3 disorders).
The challenges in developing novel therapeutics for psychiatric disorders result from the 
paucity of novel, valid targets. This results from etiological heterogeneity, the complex and 
polygenic nature of genetic risk and the definition of psychiatric disorders based on the 
range and duration of symptoms (that are subjective, self-reported or observational). In 
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addition, the complexity of the human brain means that large gaps exist in our knowledge of 
how brain expressed biochemical pathways relate to identified brain circuits and neuronal 
networks. The few examples of aetiology relevant higher order human behavioural 
functional domains and behavioural quantitative trait dimensions4 limit the potential targets 
and measurable readouts that can used in animal and human experimental medicine studies. 
While target identification based on genetics and biology looks increasingly feasible, 
concerns about the validity of existing model systems, especially rodents, have hampered the 
assessment of the value of potential new drug targets (target qualification) and have led to 
calls for proof of concept human studies as the ultimate approach in hypothesis testing for 
target validation.5 However clinical proof-of concept validation studies are expensive and 
carry risk, and will always be limited in number. Other challenges arise from the lack of 
informative biomarkers to guide proof of concept clinical studies and clinical development 
(for example by patient stratification), subjective clinical endpoints, and high placebo 
response rates (particularly in major depression)6.
What can genetic studies offer for drug discovery?
Human genetic studies have made tremendous progress in identifying loci linked to human 
disorders. Outside of psychiatry, these include high-risk mutations in single genes that 
identify specific targets for manipulation4. These include PCSK9, where individuals with 
‘knockout’ mutations have lower LDL cholesterol without obvious deleterious effects, that 
has led to promising results in clinical trials7, loss of function mutations in SLC30A88 
which reduce the risk of type 2 diabetes, and loss of function LPA mutations which reduce 
plasma lipoprotein(a) levels and cardiovascular disease risk.9
With the notable exception of autism with intellectual disability, however, rare mutations 
account for a relatively small proportion of cases in psychiatry, although this varies among 
disorders and their exact contribution is debated. Where they have been found, there is 
evidence that they converge on the same biological pathways as common variants: genes in 
schizophrenia GWAS associated regions overlap with those identified by sequencing studies 
focussed on de-novo damaging mutations in intellectual disability and autism101112.
It may be more straightforward to identify a new target via rare mutations, but it is often not 
clear whether manipulating these targets will be effective in the wider disease population. 
The common disease-associated polymorphisms identified by GWAS in psychiatry and other 
complex disorders also have the potential to identify novel drug targets as well as new 
aetiologies that can kindle the generation of new model systems for therapeutic development 
in the wider population.13 Several examples indicate that although GWAS loci have small 
effect sizes, they nonetheless may help identify targets for novel therapeutics, as shown in 
GWAS meta-analyses of lipid levels,14 or existing drugs that can be repurposed for the 
treatment of diseases that they were not initially developed to treat, an approach known as 
drug repositioning15,16. Integration of genetic data can be used for target selection, matching 
targets to indications while allowing a reduction in clinical trial costs such as by allowing 
more accurate identification of high risk individuals. Targets with genetic support have been 
shown to have a higher chance of success17.
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What genomics can offer
The discovery of common genetic variants associated with risk for psychiatric illness has the 
capability of restarting hypothesis-led drug discovery. As for other complex genetic 
disorders, the application of human genetics to schizophrenia, led by the PGC (URLs), has 
identified multiple disease susceptibility loci with increasing sample sizes. In 2014, over 100 
robustly associated loci were identified through case-control GWAS meta-analysis by the 
PGC10. Similar progress is underway in other psychiatric disorders, with new successful 
GWAS reports expected for ADHD, autism, major depressive disorder, anorexia nervosa, 
and bipolar disorder in the next year.
The discovery of GWAS loci for these disorders is likely to continue for many years to come 
with, ultimately, many hundreds or thousands of independent genetic associations expected 
for each disorder18. This does not mean the whole genome will eventually be implicated - 
rather we expect thousands of physically overlapping and independently associated loci to 
cluster onto hundreds of gene regions. The available evidence suggests these hits will 
converge onto both specific genes and biological pathways.
Insight into which genes (and which gene-products) are implicated and the direction of 
effect is needed to determine the most appropriate therapeutic strategy. A general 
understanding of the additional steps in the target identification and qualification process has 
developed: GWAS locus-to-gene mapping to determine which gene(s) give rise to the 
association, plus functional studies of how the disease-associated SNPs operate (modality), 
either via regulatory effects (e.g. affecting RNA splicing or levels) or through direct 
functional effects (affecting the nature and function of a protein). In this way, therapeutics 
targeting single GWAS identified targets, such as HMGCR in the LDL cholesterol 
metabolism responsible for hypercholesterolemia19, have been successfully developed. This 
process is beginning for schizophrenia20, and the PGC aims to accelerate this for all 
psychiatric disorders.
One problem is that GWAS hits identify variants, usually SNPs, that mark regions of the 
genome, so-called ‘loci’, but in most cases do not directly identify the genes themselves nor 
their causal alleles. A GWAS locus often includes multiple genes within the region of 
statistical significance, and a hit within a gene does not guarantee that that is the gene 
involved; the functional effect of the variants is not usually obvious, and it may even have a 
regulatory effect on a gene outside the GWAS risk locus. Data from large scale genomic and 
systems biology experiments are being used to identify expression, protein and methylation 
quantitative trait loci (e, p and m-QTLs) to try to better map causal alleles2122. This includes 
imputation of gene expression profiles2324. A caveat is that linkage disequilibrium between 
markers often results in multiple genes in a region being implicated by expression 
imputation, recapitulating the initial problem. In addition, the lack of large samples of 
available brain tissues from both patients and healthy donors at appropriate stages of 
development as yet hampers the wide scale application of this approach, although the 
CommonMind (http://commonmind.org) and Brainseq25 initiatives are taking strides in this 
direction (discussed below). It remains the case that each GWAS locus requires careful and 
bespoke examination (see Geschwind et al this issue26).).
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The available data indicate that psychiatric disorders are highly ‘polygenic’ and we now 
expect hundreds or thousands of individual variants to be associated with each disorder. A 
promising strategy to deal with the small effect sizes and plethora of results is to adopt a 
pathway- and network-informed interpretation of GWAS hits. An analysis by Cao and 
Moult27 found that while only a small fraction of known drug targets are in GWAS loci (12 
of 353 drug targets for 81 diseases), known drug targets are enriched three-fold in the 
nearest neighbour interactors (proteins that physically interact with a given protein) of genes 
in GWAS loci and are also enriched in second order interactors. This is supported by GWAS 
results in type 2 diabetes28 which found that pathways targeted by anti-diabetes drugs are 
enriched in genes from GWAS and their direct protein interactors. This pool of GWAS hits, 
their interacting partners and networks provides a resource for the identification of novel 
drug targets and for drug repositioning.
How can genetic and genomic data be used in the psychiatric drug 
development pipelines?
A critical issue in the field is how to use genetics information to drive drug discovery. As 
reviewed above, it often is not clear what genes are driving the association for GWAS 
significant loci. A potentially paradigmic example has recently emerged. C4 copy number 
was recently confirmed as a schizophrenia risk locus potentially affecting synaptic pruning 
in neurodevelopment; this study used PGC2 schizophrenia GWAS data, expression data 
from 700 postmortem brains, and genetic engineering of mice to confirm a potential 
mechanism20. This is already encouraging the development of new therapeutics, because 
synaptic pruning occurs as the brain develops to full maturity in the late teens/early 
adulthood, providing time during which therapeutic interventions may be possible.
Relatively few GWAS hits have thus far been studied in such detail. However, much GWAS 
evidence converges on particular biological pathways which are in themselves more 
druggable than single genes29. The pharmaceutical industry has also embarked on efforts to 
understand gene associations and the biological pathways impacted5. We need to link risk 
loci information to our understanding of pathways to help identify relevant biological 
processes, cell-types and brain circuits and to hone in on new molecular hypotheses and 
possible novel targets30. This need has sparked several academic projects and industry-
academia pre-competitive collaborations. There are currently a large number of open-source 
and/or publically available efforts. These include large databases, ranging from ChEMBL. 
DiGB, Drug Bank to KiDB from the Psychoactive Drug Screening Program (listed in Table 
c), which serve as portals for identifying known molecular targets of drugs and drug-like 
small molecules. PHAROS (https://pharos.nih.gov/idg/index; http://targetcentral.ws/) is a 
new resource enabled by the NIH Druggable Genome Initiative, which serves as a portal for 
a variety of useful information regarding druggable targets. Likewise the Open Targets 
(formerly the Centre for Therapeutic Target Validation) public-private initiative in the UK 
integrates a large number of data sources into one searchable platform for single targets 
(https://www.targetvalidation.org/).
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In order to enable the integration of functional genomic data from post-mortem brain 
samples from cases and controls new technologies are needed that enable the accurate 
identification of cell type specific omics profiles and individual level neuronal circuitry. Key 
examples driving the generation of large relevant datasets are industry-academia 
partnerships including the BrainSeq25, CommonMind (URLs), and psychENCODE (URLs) 
projects, which allow investigators to map genes identified in GWAS onto transcriptomics in 
postmortem tissue from controls and cases with schizophrenia or bipolar disorder (as well as 
iPSC neuronal cell lines from cases and controls31). A primary goal is to elucidate molecular 
mechanisms driven by risk variants with the additional benefit that using genetic data can 
allow causal anchoring of molecular changes and pathology thus avoiding incidental, 
downstream effects of the disorders themselves and their treatments25.
In order to advance our ability to understand GWAS data, the field will need to undertake 
further large-scale efforts to generate sufficient functional characterization of changes in 
brain gene and protein expression in patients and during development, and to move beyond 
schizophrenia and bipolar disorder to address many other disorders. The exploration and 
availability of large patient data sets is valuable. There are a number of initiatives in large, 
deeply phenotyped longitudinal samples aimed at mapping psychiatric genetic discoveries 
onto imaging, neurophysiological, and behavioral traits, to establish aetiologically related 
intermediate phenotypes that could be useful in the development of novel therapeutics. 
These and many other efforts aimed at linking genetic variations associated with risk with 
circuitry and molecular targets are a needed next step.
Precision medicine for psychiatry and polygenic risk scores
The customization of diagnosis and treatment to individuals - is likely to have a role in 
clinical psychiatry. However, the extent to which this will be important and the proportions 
of individuals with a particular psychiatric disorder who might benefit from precision 
medicine is unclear and is now the subject of considerable research. Genomics is an 
important tool in the precision medicine toolbox. It is already important for several disorders 
and becoming common in clinical practice (e.g., in the evaluation of children with 
intellectual disability and pervasive developmental delay). However, these studies are mostly 
focused upon rare genetic variants of uncommonly large effect. For most individuals with 
serious psychiatric disorders whose risk is mediated by the cumulative effect of large 
numbers of common genetic variant with or without important environmental impacts, it is 
not yet clear whether genomics will be an important part of precision medicine in psychiatry. 
We know that these genetic effects significantly impact risk10,29 but the effects are not 
deterministic.
An key approach is to use polygenic risk scores (extensively reviewed and discussed 
elsewhere32). A polygenic risk score (PRS)33 is an approximate measure of an individual’s 
common variant genetic propensity for a given disorder and, at a population level shows 
some predictive power34 for case-control status. PRS approaches provide several potential 
routes to drug development, including identification of genetically associated 
endophenotypes and biomarkers. PRS can also be exploited to improve clinical trial efficacy. 
Super controls can be chosen by selecting participants with very low PRS for the disease, or 
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PRS for low risk of side-effects or where differential diagnosis is unclear. This may convey 
particular benefit in trials for diseases such as Alzheimer’s (being investigated by a new 
workgroup in the PGC), where defining cases and controls is challenging. Furthermore, 
prevention trials could enlist high risk individuals from the top end of the PRS distribution35, 
which, amongst other benefits, may be less expensive and confounded than the sibling 
design36. Current studies in psychiatry are attempting to improve prediction of diagnosis or 
treatment response, for example in first episode psychosis37.
PGC phase 3: Target identification in Psychiatric GWAS data
To fully exploit GWAS data for drug development, we need to complement the direct 
identification of single targets and their interactors and the use of polygenic risk scores with 
pathway-driven approaches, explicitly targeting sets of GWAS implicated regions/proteins 
together. In our view, this may be a powerful means to discover new drug indications/targets 
that gains power by exploiting the underlying polygenic nature of these disorders. This 
mirrors the observation that many successful psychiatric (and other) drugs have complex 
receptor pharmacology profiles binding multiple targets with different affinities. The PGC is 
planning to exploit pathway analysis methods38 that show better control for type 1 error 
alongside chemoinformatically generated gene sets to identify drugs or molecules with sets 
of targets significantly enriched for association in GWAS data. Applying drug pathway 
analyses to psychiatric GWAS results will allow us to derive hypotheses about drug 
mechanisms of action and rational drug repurposing39. Rare variants, discovered by large 
scale sequencing efforts, can also be included in these analyses, particularly the known 
recurrent Copy Number Variations in Autism and Schizophrenia40. These are complemented 
by ongoing large scale sequencing efforts in these disorders. Although rare mutations are 
only found in a small percentage of cases with most common disorder4142, integrative 
pathway analysis including common and rare variants might increase power to detect 
statistically significant enriched pathways.
Using these data sources, three broad strategies are possible (see Figure 1). First, pathway 
analysis using the genetic variants found to be associated with psychiatric disorders using 
gene-sets (pathways) annotated for their drug associations or corresponding to sets of 
ligands in publically available resources such as ChEMBL and KiDB to test whether these 
gene sets together harbour a significant association signal using the PGC pathway analysis 
pipeline43. Second, use relevant gene expression profiles identified from case-control 
transcriptome data and examine their similarity to induced gene expression changes in cell 
lines, as identified by the NIH LINCS project (URLs) or in studies of neuronal cells derived 
from iPSC, to identify potential pathways and molecules which impact the expression and/or 
function of identified targets44. This strategy of ‘connectivity mapping’ allows identification 
of compounds with a similar or opposite effect on gene expression as our findings and can 
point to possible new treatment targets. Finally, we can layer onto these approaches 
“traditional” pathway annotations and ontologies (particularly GO and REACTOME) and 
newer data sources that may be less biased and more complete45 to allow us to develop a 
mechanistic understanding.
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Conclusions
These approaches require substantial and integrated efforts, involving consortia such as the 
PGC, other academic groups, and industry in pre-competitive framework to drive forward 
target identification and qualification to the point where confidence will be high enough to 
begin a clinical validation process; sharing of data and expertise will be essential. It will 
only be through collaborative work that the field will muster enough breadth of data and 
resources for this effort to fulfill its translational potential beyond polygenic risk score and 
prediction, to the identification of new biology and eventually towards resolving the current 
blockages in psychiatric drug discovery.
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Figure 1. 
PGC GWAS Drug Target Analysis Strategy: utilising diverse information sources for drug 
target discovery.
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Table 1
Large and commonly used chemoinformatics resources.
Name Bioactivities Link Summary Last updated
ChEMBL Various bioactivities (KtoEC50…) https://www.ebi.ac.uk/chembl/ ~1.6M 
compounds, 
14M 
activities, 
11K targets
2016
KiDB Ki http://kidbev.med.unc.edu/databases/kidb.php ~10K 
compounds, 
59K 
interactions, 
738 target
2016
Binding DB Various bioactivities https://www.bindingdb.org/bind/index.jsp ~542K 
compounds, 
1.2M 
activities, 
5K targets
2016
PhannGKB Drug response data https://www.pharmgkb.org/ – 2016
Guide to Pharmacology Various bioactivities https://www.guidetopharmacology.org/ ~8K 
compounds, 
14K 
bioactivities, 
2.7K targets
2016
DrugBank Drug/target interactions http://www.drugbank.ca/ ~8K drugs, 
15K drug/
target 
associations, 
4K targets
2016
CTD Chemical gene interactions, gene-
disease and chemical disease 
associations
http://www.ctdbase.org/ ~14M 
chemical 
gene 
interactions, 
20M gene-
disease 
associations, 
2M 
chemical-
disease 
associations
2016
STITCH Association scores http://stitch.embl.de/ new beta:http://stitch-beta.embl.de/ interactions 
between 
300K small 
molecules 
and 2.6K 
proteins 
from 1133 
organisms
2016
PubChem Various bioactivities https://pubchem.ncbi.nlm.nih.gov/ ~2M 
compounds, 
230M 
bioactivities, 
10K targets
2016
PHAROS Various bioactivities, target 
disease score
https://pharos.nih.gov/ ~134K 
compounds, 
140K 
bioactivities, 
1.8K 
targets, 
2.6K 
diseases
2016
Open Targets Target-disease and drug-target 
associations
https://www.targetvalidation.org/ ~2.1M 
target-
2016
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Name Bioactivities Link Summary Last updated
disease 
associations 
covering 
7.9K 
diseases and 
25K targets
DGIdb Drug/gene interactions http://dgidb.genome.wustl.edu/ Without 
PharmGKB: 
~12K 
compounds, 
26K 
structure/
gene pairs, 
~3.1K 
targets
2016
CARLSBAD CARLSBAD activity http://carlsbad.health.unm.edu/ ~435K 
structures, 
933K 
structure/
target pairs, 
3.7K targets
2014
ChemProt ChemProt activity http://potentia.cbs.dtu.dk/ChemProt/ ~1.7M 
structures, 
7.8M 
structure/
target pairs, 
19K targets
2016
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